Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. [electronic resource]
Producer: 20200324Description: 1-7 p. digitalISSN:- 1090-2104
- Animals
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Hepatocellular -- drug therapy
- Cell Line, Tumor
- Female
- Fibroblast Growth Factors -- metabolism
- Humans
- Liver Neoplasms -- drug therapy
- MAP Kinase Signaling System -- drug effects
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Phenylurea Compounds -- therapeutic use
- Quinolines -- therapeutic use
- Receptors, Fibroblast Growth Factor -- metabolism
- Signal Transduction -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.